Validation period: 11/26/2022, 3:36:53 PM - 11/26/2022, 9:36:53 PM
BMJ Journals logo
Email alerts

The Journal for ImmunoTherapy of Cancer

is an open access journal that publishes high quality research, literature reviews, position papers and practice guidelines, and case studies on all components of cancer immunology and immunotherapy.

Impact Factor: 12.469
Citescore: 14.3
All metrics >>

The Journal for ImmunoTherapy of Cancer (JITC) is an open access, peer-reviewed journal that aims to enrich communication and advance scientific understanding in the rapidly evolving fields of tumor immunology and cancer immunotherapy. Topics of interest range across the basic science-translational-clinical spectrum and include tumor-host interactions, the tumor microenvironment, animal models, predictive and prognostic immune biomarkers, novel pharmaceutical and cellular therapies, vaccines, combination immune-based therapies, and immune-related toxicity.

JITC is the official journal of the Society for Immunotherapy of Cancer (SITC).   View the SITC 37th Annual Meeting (SITC 2022) Abstracts here.

EDITOR-IN-CHIEF
Pedro J. Romero, MD, University of Lausanne
Editorial Board

Current IssueJournal Current Issue

Highlighted Articles

Featured image for article, title: Loss of secreted gelsolin enhances response to anticancer therapies
Loss of secreted gelsolin enhances response to anticancer therapies

Authors

The Journal for ImmunoTherapy of Cancer accepts a variety of article types in a number of formats.

The Author Information section provides specific article requirements and section outlines to help you turn your research into an article suitable for JITC.

Information is also provided on editorial policy, Open Access fees and formatting.

A guide to publishing in JITC

Author informationSubmit a paper

Twitter Feed

Imaging and Immunotherapy

Review:

Artificial intelligence and radiomics: fundamentals, applications, and challenges in immunotherapy

30 September 2022

Latest Articles

Altmetrics

altmetric badge
Spontaneous tumor regression following COVID-19 vaccination
3 March 2022

What Our Editors Are Reading

In JITC’s Reading List, JITC editors provide a monthly list of publications in other journals that have their attention and add value to what readers may find in JITC. Read what has piqued the interest of this month’s featured editor in the latest Reading List.

JITC Reading List

About SITC

SITC Society Logo

The Society for Immunotherapy of Cancer (SITC) is the world’s leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. As a way to thank the SITC members who work tirelessly to advance the science and improve the lives of cancer patients, SITC provides members with a 50% discount on Article Processing Charges (APCs) for all JITC articles submitted and accepted in 2022. This discount is applied post-acceptance, at which point a discount code is shared with the corresponding author.

Note: JITC also offers full waivers for the APC (100% discount of the APC) where all authors are based in low-income countries (see policy). Requests for waivers must be made prior to submission. For additional information regarding these discounts, as well as institutional arrangements, view the journal's APC policy.

SITC Society Logo
CONTENT
  • Latest content
  • Browse by collection
  • Archive
  • Top cited articles
rss-icontwitter-iconlinkedin-icon
bmj-footer-logo
Website Terms & ConditionsPrivacy & CookiesContact BMJCookie settingsOnline ISSN: 2051-1426Copyright © 2022 BMJ Publishing Group Ltd and Society for Immunotherapy of Cancer. All rights reserved.